Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-22-015421
Filing Date
2022-10-26
Accepted
2022-10-26 17:00:22
Documents
9
Period of Report
2022-11-16

Document Format Files

Seq Description Document Type Size
1 DEF 14A tmb-20221116xdef14a.htm DEF 14A 252689
2 GRAPHIC tmb-20221116xdef14a008.jpg GRAPHIC 2625
3 GRAPHIC tmb-20221116xdef14a002.jpg GRAPHIC 4439
4 GRAPHIC tmb-20221116xdef14a006.jpg GRAPHIC 2788
5 GRAPHIC tmb-20221116xdef14a011.jpg GRAPHIC 126483
6 GRAPHIC tmb-20221116xdef14a001.jpg GRAPHIC 5724
7 GRAPHIC tmb-20221116xdef14a007.jpg GRAPHIC 2746
8 GRAPHIC tmb-20221116xdef14a004.jpg GRAPHIC 5243
9 GRAPHIC tmb-20221116xdef14a010.jpg GRAPHIC 89572
  Complete submission text file 0001558370-22-015421.txt   584953
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39069 | Film No.: 221333915
SIC: 2834 Pharmaceutical Preparations